Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction von Bays, Harold

Volltext

Adiposopathy is "sick fat" a cardiovascular disease? von Bays, Harold E

Volltext

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus von Bays, Harold

Volltext

“Sick Fat,” Metabolic Disease, and Atherosclerosis von Bays, Harold E., MD

Volltext

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol von Ray, Kausik K, Bays, Harold E, Catapano, Alberico L, Lalwani, Narendra D, Bloedon, LeAnne T, Sterling, Lulu R, Robinson, Paula L, Ballantyne, Christie M

Volltext

Clinical Overview of Omacor: A Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids von Bays, Harold

Volltext

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report von Jacobson, Terry A., MD, Ito, Matthew K., PharmD, Maki, Kevin C., PhD, Orringer, Carl E., MD, Bays, Harold E., MD, Jones, Peter H., MD, McKenney, James M., PharmD, Grundy, Scott M., MD, PhD, Gill, Edward A., MD, Wild, Robert A., MD, PhD, Wilson, Don P., MD, Brown, W. Virgil, MD

Volltext

Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity von Bays, Harold E., Kozlovski, Plamen, Shao, Qing, Proot, Pieter, Keefe, Deborah

Volltext

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial von Hollander, Priscilla, Bays, Harold E, Rosenstock, Julio, Frustaci, Mary Ellen, Fung, Albert, Vercruysse, Frank, Erondu, Ngozi

Volltext

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus von Bays, Harold E., Weinstein, Richard, Law, Gordon, Canovatchel, William

Volltext

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary von Jacobson, Terry A., MD, Ito, Matthew K., PharmD, Maki, Kevin C., PhD, Orringer, Carl E., MD, Bays, Harold E., MD, Jones, Peter H., MD, McKenney, James M., PharmD, Grundy, Scott M., MD, PhD, Gill, Edward A., MD, Wild, Robert A., MD, PhD, Wilson, Don P., MD, Brown, W. Virgil, MD

Volltext

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy von Ballantyne, Christie M, Laufs, Ulrich, Ray, Kausik K, Leiter, Lawrence A, Bays, Harold E, Goldberg, Anne C, Stroes, Erik SG, MacDougall, Diane, Zhao, Xin, Catapano, Alberico L

Volltext

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) von Ballantyne, Christie M., MD, Bays, Harold E., MD, Kastelein, John J., MD, PhD, Stein, Evan, MD, PhD, Isaacsohn, Jonathan L., MD, Braeckman, Rene A., PhD, Soni, Paresh N., MD, PhD

Volltext

Safety Considerations with Omega-3 Fatty Acid Therapy von Bays, Harold E., MD

Volltext

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial von Bhatt, Deepak L., Bays, Harold E., Miller, Michael, Cain, James E., Wasilewska, Katarzyna, Andrawis, Nabil S., Parli, Teresa, Feng, Shibao, Sterling, Lulu, Tseng, Leo, Hartsfield, Cynthia L., Agollah, Germaine D., Mansbach, Hank, Kastelein, John J. P.

Volltext

Adiposopathy, Diabetes Mellitus, and Primary Prevention of Atherosclerotic Coronary Artery Disease: Treating “Sick Fat” Through Improving Fat Function with Antidiabetes Therapies... von Bays, Harold E., MD

Volltext

Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week stud... von Bays, Harold E., MD, Ballantyne, Christie M., MD, Kastelein, John J., MD, PhD, Isaacsohn, Jonathan L., MD, Braeckman, Rene A., PhD, Soni, Paresh N., MD, PhD

Volltext

Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials von Jones, Peter H., Bays, Harold E., Chaudhari, Umesh, Pordy, Robert, Lorenzato, Christelle, Miller, Kathryn, Robinson, Jennifer G.

Volltext

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance von Nicholls, StephenJ, Lincoff, A Michael, Bays, Harold E, Cho, Leslie, Grobbee, Diederick E, Kastelein, John JP, Libby, Peter, Moriarty, Patrick M, Plutzky, Jorge, Ray, Kausik K, Thompson, Paul D., Sasiela, William, Mason, Denise, McCluskey, Jaclyn, Davey, Deborah, Wolski, Kathy, Nissen, Steven E

Volltext

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial von Bays, Harold, Gaudet, Daniel, Weiss, Robert, Ruiz, Juan Lima, Watts, Gerald F, Gouni-Berthold, Ioanna, Robinson, Jennifer, Zhao, Jian, Hanotin, Corinne, Donahue, Stephen

Volltext